Acrivon Therapeutics, Inc. (ACRV)
NASDAQ: ACRV · Real-Time Price · USD
7.85
-0.16 (-2.00%)
Nov 4, 2024, 4:00 PM EST - Market closed

Acrivon Therapeutics Cash Flow Statement

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
TTM FY 2023 FY 2022 FY 2021 FY 2020
Period Ending
Jun '24 Dec '23 Dec '22 Dec '21 Dec '20
Net Income
-69-60.39-31.17-16.24-5.31
Depreciation & Amortization
0.730.540.360.040.01
Loss (Gain) From Sale of Investments
-3.1-3.32-0.7--
Stock-Based Compensation
13.211.622.190.50
Other Operating Activities
0.850.780.731.42.17
Change in Accounts Payable
0.033.61-0.250.80.08
Change in Other Net Operating Assets
4.144.53-1.29-0.470.24
Operating Cash Flow
-53.16-42.64-30.12-13.98-2.8
Capital Expenditures
-2.1-1.29-2.17-0.24-0.02
Investment in Securities
-58.0452.01-139.51--
Investing Cash Flow
-60.1450.72-141.68-0.24-0.02
Long-Term Debt Issued
----0.06
Net Debt Issued (Repaid)
----0.06
Issuance of Common Stock
70.480.78104.480-
Repurchase of Common Stock
-1.97-1.3---
Other Financing Activities
52.74-1.03-2.77--
Financing Cash Flow
121.25-1.55101.71112.222.89
Net Cash Flow
7.956.52-70.08980.07
Free Cash Flow
-55.26-43.93-32.28-14.22-2.82
Free Cash Flow Per Share
-2.14-1.99-7.83-8.16-1.97
Levered Free Cash Flow
-31.31-22.33-20.03-8.79-
Unlevered Free Cash Flow
-31.31-22.33-20.03-8.79-
Change in Net Working Capital
-4.55-8.75-0-1.03-
Source: S&P Capital IQ. Standard template. Financial Sources.